Health Technology Assessment (HTA) has become a central instrument for evidence-informed healthcare decision-making, supporting reimbursement, pricing, prioritization, and resource allocation across health systems facing increasing clinical, economic, and societal pressure. The internationally accepted definition of HTA describes it as a multidisciplinary process that uses explicit methods to determine the value of health technologies at different points in their lifecycle, with the purpose of promoting equitable, efficient, and high-quality health systems . This definition is especially relevant today, as precision medicines, immunotherapies, cell and gene therapies, diagnostics, digital health interventions, and preventive technologies create new opportunities for patients while intensifying questions about affordability, access, uncertainty, and long-term value.
Traditional HTA frameworks have relied primarily on clinical endpoints, safety outcomes, cost-effectiveness analyses, and budget impact assessments. These dimensions remain indispensable, but they do not always capture the full impact of health technologies on everyday life. Symptom burden, physical functioning, emotional wellbeing, autonomy, treatment convenience, caregiver impact, social participation, and patient preferences may be highly relevant to patients even when they are only partially reflected in conventional endpoints. Technology may improve a clinical outcome while imposing substantial treatment burden; conversely, an intervention with modest clinical effects may produce meaningful gains in reassurance, adherence, functioning, or quality of life. Contemporary HTA is therefore evolving from a predominantly technical assessment of effectiveness and efficiency into a more multidimensional and deliberative process.
Patient-reported outcomes (PROs), patient-reported outcome measures (PROMs), patient experience, and meaningful patient involvement are central to this evolution. Patient-centered HTA should not be reduced to the mechanical inclusion of questionnaires or utility values. Rather, it requires both robust evidence about patient perspectives and effective engagement of patients in scoping, evidence generation, value assessment, recommendation development, and dissemination. Recent patient-reported surveys illustrate why this matters: chronic disease burden may remain substantial despite advanced therapy use, affecting quality of life, work productivity, mental health, treatment satisfaction, and adherence . Such evidence highlights that the value of care cannot be inferred from biomedical markers alone.
PROs and PROMs also create a bridge between clinical research and economic evaluation. Preference-based measures can inform utility estimation, while disease-specific instruments and qualitative patient evidence can explain what changes are meaningful, acceptable, or burdensome from the patient perspective. Their contribution is greatest when they are planned early, collected consistently, interpreted in context, and connected to decisions about comparators, endpoints, model assumptions, and reimbursement conditions. In this sense, patient-centered evidence should be understood not as an optional supplement to HTA, but as part of the evidence infrastructure required to assess value responsibly .
Meaningful patient involvement is broader than consultation at the final stage of appraisal. Patients and caregivers can help define the decision problem, identify relevant comparators, guide endpoint selection, interpret trade-offs between benefits and harms, and clarify which uncertainties are acceptable in practice . They can also reveal aspects of value that may otherwise remain invisible, such as travel time, monitoring burden, stigma, family disruption, financial vulnerability, and the practical usability of care. Embedding these perspectives early can improve scientific relevance and deliberative legitimacy, reducing the risk that HTA processes answer questions that are technically precise but socially incomplete.
At the same time, health systems must reconcile patient-centered value with fiscal sustainability. This is particularly evident in oncology and precision medicine, where targeted therapies and biomarker-driven treatment pathways have transformed care but also increased pressure on reimbursement systems. This evidence reinforces the need for HTA frameworks that integrate clinical benefit, patient value, real-world utilization, economic impact, and affordability.